INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE

被引：0
|
作者：
Al Awadi, F. [1 ]
Aly, H. [2 ]
Bashier, A. [1 ]
Benavente, J. Medina [3 ]
Dhanwal, D. Kumar [4 ]
Jallo, M. [5 ]
Singhal, S. [6 ]
Abusnana, S. [7 ]
机构：
[1] Dubai Hosp, Endocrinol, Dubai, U Arab Emirates
[2] Novo Nordisk Pharmaceut Co, Clin Med Regulatory Affairs & Qual, Dubai, U Arab Emirates
[3] Novo Nordisk AS, Endocrinol, Soborg, Denmark
[4] NMC Specialty Hosp, Endocrinol, Abu Dhabi, U Arab Emirates
[5] Gulf Med Univ, Coll Med, Clin Sci, Ajman, U Arab Emirates
[6] Novo Nordisk, Clin Med Regulatory Affairs & Qual, Dubai, U Arab Emirates
[7] Univ Sharjah, Endocrinol, Sharjah, U Arab Emirates
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2022年 / 186卷
关键词：
D O I：
10.1016/j.diabres.2022.109620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF21-0679
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Switching to Insulin Degludec Improves Glycemic Control in Patients with T2DM in a Real-World Setting
    Schultes, Bernd
    Tentolouris, Nikolaos
    Knudsen, Soren T.
    Lapolla, Annunziata
    Eidenmueller, Markus
    Prager, Rudolf
    Phan, Tra-Mi
    Wolden, Michael L.
    Siegmund, Thorsten
    DIABETES, 2017, 66 : A266 - A266
  • [2] Real-world use of insulin degludec/liraglutide (IDegLira) significantly improves glycaemic control in patients with Type 2 diabetes
    Feher, M.
    Price, H.
    Schultes, B.
    Prager, R.
    Phan, T. M.
    Thorsted, B. L.
    Bluher, M.
    DIABETIC MEDICINE, 2018, 35 : 158 - 158
  • [3] Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
    Price, Hermione
    Blueher, Matthias
    Prager, Rudolf
    Phan, Tra-Mi
    Thorsted, Brian L.
    Schultes, Bernd
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 954 - 962
  • [4] Real-World Effectiveness, Adherence, and Persistence among Patients with T2DM Initiating Dulaglutide
    Mody, Reema
    Grabner, Michael
    Yu, Maria
    Turner, Ralph
    Kwan, Anita
    York, Whitney
    Lando, Laura Fernandez
    DIABETES, 2017, 66 : A355 - A355
  • [5] Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study
    Abusnana, Salah
    Al Awadi, Fatheya
    Aly, Hazem
    Bashier, Alaaeldin
    Dhanwal, Dinesh Kumar
    Halasa, Tariq
    Jallo, Mahir
    Medina, Johan
    Singhal, Sagar
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 196
  • [6] Remogliflozin in Indian T2DM Patients: A Real-World Study
    Bhattacharya, Supratik
    Katare, Sagar
    DIABETES, 2020, 69
  • [7] REAL-WORLD ADHERENCE IN MEDICARE PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOR EXENATIDE QW AND LIRAGLUTIDE QD
    Tarr, A.
    Nguyen, H.
    Dufour, R.
    Bullano, M.
    VALUE IN HEALTH, 2015, 18 (03) : A57 - A57
  • [8] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence
    Mezquita Raya, Pedro
    Ampudia Blasco, Francisco Javier
    Hunt, Barnaby
    Martin, Virginia
    Larsen Thorsted, Brian
    Basse, Amaury
    Price, Hermione
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1349 - 1356
  • [9] A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM
    Mahapatra, H.
    Dalai, S.
    Sahoo, A.
    Khuntia, M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [10] Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
    Paola Ponzani
    Cesare Berra
    Alessandra Di Lelio
    Paola Del Sindaco
    Chiara Di Loreto
    Francesco Reggiani
    Giuseppe Lucisano
    Maria Chiara Rossi
    Diabetes Therapy, 2018, 9 : 2209 - 2218
12345